PubMed Health⌕ Search

PubMed · 16800678

Trapping silicon surface-based radicals.

Abstract

The spontaneous one-electron reduction of diazonium salts on hydride-terminated porous silicon (pSi) and flat silicon produces surface radicals that can be trapped chemically. These silicon radicals react with reagents such as alkyl/arylselenoethers, alkenes, alkynes, and alkylbromide groups to generate covalently bound functionalities in a manner analogous to the chemistry of molecular-based silicon radical species, prepared via different methods. When pSi is exposed to an acetonitrile solution of any of the three diazonium salts examined in this study, aryl groups from the diazonium precursor become covalently bound and significant oxidation is noted; if, however, a reactive trapping agent is added, such as an alkyl/arylselenoether or a carbon-carbon unsaturated bond, no aryl group attachment is observed and oxidation is circumvented due to the efficiency of the trapping chemistry. The reactions proceed rapidly, in less than 3 h to maximum coverage, at room temperature. The diazonium salt-initiated radical reaction with alpha,omega-alkenes and alkynes tolerates various functional groups including aryl, diene, diyne, carboxylic acid, and hydroxyl, reacting exclusively via the carbon-carbon unsaturated bond; alpha,omega-bromoalkenes are not, however, compatible with this chemistry. A silicon-based molecule, tris(trimethylsilyl)silane, in the presence of a diazonium salt initiator and a primary alkyne does not lead to the hydrosilylation product but to tris(trimethylsilyl)silylbromide and the hydrogenated arene, derived from the diazonium. The difference in reactivity between the molecule and the surface is due to the fact that the silicon surface is a source of electrons to reduce the diazonium salts to aryl radicals, whereas a heterolytic pathway is followed in the molecular silane case.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Dong Wang, Jillian M Buriak. 2006-07-04. Trapping silicon surface-based radicals.. https://doi.org/10.1021/la060653e

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗